Redeye reviews the case in Annexin Pharmaceuticals and raises fair values significantly, following the long-awaited step into the clinic. The company has taken critical steps to explore the vast therapeutic potential with its lead candidate, ANXV. The transition into a clinical-stage biotech was not rewarded by the stock market, which surprised us, and our updated Base Case entails a significant upside from current share levels.